RE:Type C Meeting TimingsAt the 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat on May 15, 2024, Matt Coffey stated that the FDA Type C meeting with a focus on ONCY's planned registration-enabling trial for pelareorep in breast cancer was scheduled for approximately 35 days after the date of request. So we should expect to be hearing more about the outcome of this Type C meeting sometime next week.
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-advances-toward-registration-enabling-trial-for-pelareorep-in-breast-cancer-with-submission-of-type-c-meeting-request-to-fda-2/